Cytodyn Inc (CYDY)

[Saltz]

The most concerning question I would have as a SH for 2022 is how is NP going to continue raising $ to keep the boat afloat.

This is NP’s strong suit - raising $. He has always been able to put together some type of deal to entice investors. The head wind is obvious. As authorized shares continue to increases the pressure on the SP increases and the investment becomes less attractive from a valuation perspective. It will become increasingly taxing on the CYDY balance sheet to raise money because the raises or going to be a gut punch.

Bottom line is what is the salvage value of the molecule if CYDY becomes insolvent and is forced to close up shop. That’s what SH’s are going to divi up if the bottom falls out.

The company can always cut expenses back to a trickle but that will cut the advancement of the molecule to a snails pace.

If one looks at the progression of Pro-140 to LL to present the barrier has always been the lack of resources and skill to expedite trials and navigate the FDA process. How in the world is LL going to make it across the finish line on a tightening budget with NP at the controls. I think that formula has been proven to be futile.

The market is saying the same thing with the SP sinking below $1.